ISTH 2013


The XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH)
took place June 29 through July 4, 2013, in Amsterdam, The Netherlands.


Product shows comparable efficacy in hemophilia A

HT Staff Read Article
Published: 07/09/13

Newly reported data suggest a recombinant factor VIII Fc fusion protein (rFVIIIFc) can treat bleeding in hemophilia A at least as well as currently available therapies. Previously released results of this phase 3 study, called A-LONG, indicated that rFVIIIFc (Eloctate) can control and prevent bleeding in males with hemophilia A. The data also showed that rFVIIIFc stays in the body 50% longer than a full-length recombinant factor VIII product (Advate). [Read Article]

FVIII product has promising PK and safety profiles, study suggests

HT Staff Read Article
Published: 07/09/13

Vials and a syringe

An investigational recombinant single-chain factor VIII product (rVIII-SingleChain) has a longer half-life than octocog alfa, results of a new study suggest. Data from the phase 1/3 study, called AFFINITY, also indicate that rVIII-SingleChain is well tolerated in patients with severe hemophilia A. Ingrid Pabinger-Fasching, MD, of the Medical University of Vienna in Austria, and her colleagues presented these results at the 2013 ISTH Congress as poster PB 2.55-4. [Read Article]

Fusion protein controls surgery-related bleeding in hemophilia B

HT Staff Read Article
Published: 07/07/13

Team performing surgery
Credit: Piotr Bodzek

A recombinant factor IX Fc fusion protein known as eftrenonacog alfa (Alprolix) can control bleeding among hemophilia B patients undergoing major surgery, according to data from the B-LONG study presented at ISTH 2013. The goal of the phase 3 study was to evaluate the safety, efficacy, and pharmacokinetics (PK) of eftrenonacog alfa among male patients with hemophilia B. Previously released data from the study suggested . . . [Read Article]

Product can treat/prevent bleeding in hemophilia B

HT Staff Read Article
Published: 07/05/13

Bleeding wound

A recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) can prevent and treat bleeding in patients with severe hemophilia B, results of a small study indicate. The product also has a better pharmacokinetic (PK) profile than current treatment options, according to investigators. Uri Martinowitz, MD, of Chaim Sheba Medical Center in Tel Hashomer, Israel, presented data from a phase 1/2 study of rIX-FP at the 2013 ISTH Congress.  [Read Article]

Apixaban noninferior to standard therapy for VTE

HT Staff Read Article
Published: 07/02/13

Credit: NHS

The anticoagulant apixaban is noninferior to standard treatment for recurrent venous thromboembolism (VTE), results of the phase 3 AMPLIFY trial suggest. Apixaban exhibited comparable efficacy and significantly less bleeding when compared to standard therapy—initial parenteral enoxaparin overlapped with warfarin. These data were presented at the 2013 ISTH Congress in Amsterdam and published in NEJM. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}